Latest news with #Imagion
Herald Sun
2 days ago
- Business
- Herald Sun
Imagion teams up with Wayne State University for AI push into cancer detection
Imagion to collaborate with MRI experts at Wayne State University to strengthen push into AI-enabled cancer diagnostics Collaboration will establish optimised imaging protocols for Imagion's MagSense molecular-imaging-agent tech Bolsters relationship Imagion has with Siemens Healthineers, the leading manufacturer of MRI equipment Special Report : Imagion Biosystems has strengthened its push into AI-enabled cancer diagnostics through a new collaboration with leading MRI experts at Wayne State University School of Medicine in the US. Imagion Biosystem (ASX:IBX) has signed a collaborative service agreement with Dr Mark Haacke and Dr Sagar Bush to establish optimised imaging protocols for its proprietary MagSense molecular imaging agent technology. The collaboration further bolsters the existing relationship Imagion has with Siemens Healthineers, the world's leading manufacturer of MRI equipment. Both researchers have had a long-standing collaboration with Siemens and are equipped with its top-of-the-line scanners. The research will focus on quantitative MRI sequences compatible with Siemens and other commercially available MRI scanners. By combining advanced quantitative imaging with the MagSense agents, Imagion aims to enable AI-based interpretation and deliver more accurate and precise data cancer detection and patient care. With Siemens' backing, Imagion plans to incorporate the optimised MRI sequences developed by the leading researcher into its upcoming phase II clinical trial for its HER2 breast cancer imaging agent. Other key objectives of the collaborative service agreement also include: Determining the lowest dose of the MagSense imaging agent to achieve detection Establish MRI sequences and protocols optimised for MagSense Transferring the optimised protocols to clinical sites for use in the planned MagSense HER2 Phase 2 study Using quantitative imaging techniques that could net AI compatible image data to improve diagnostic accuracy 'Exciting development for the medical imaging field' Haacke has been a pioneer in the field of quantitative MRI for decades. Collaboration with his team is set to lay the foundation for future automated analysis of MagSense images using AI. By implementing quantitative MR imaging techniques, Imagion said the specific signature of MagSense imaging agents will be uniquely detectable in affected tissue. By applying advanced post-processing techniques and AI interpretation to these images, MagSense has potential to enable not only automatic detection and differentiation of normal versus cancerous tissue, but also improved staging, tracking and treatment monitoring. 'Imagion's MagSense imaging agents are a very exciting development for the medical imaging field as it finally brings molecular specificity to MRI,' said Haacke. 'I have spent decades developing quantitative, high-resolution imaging to identify new biomarkers and explore disease etiology. 'Working with Imagion is a natural extension of that work, adding increased specificity to the already high resolution and sensitivity of MRI and powering the future of AI-based diagnostics.' Listen : Tim Boreham interviews IBX Solving a key barrier holding back AI diagnostics Imagion said conventional MRI, while producing excellent images of soft tissue, is qualitative by nature. This means it relies on subjective interpretation by radiologists to make a diagnostic determination based on differences in contrast of the various tissues. As a result, imaging findings still require confirmatory biopsies to achieve diagnostic certainty, creating challenges in analysing small lesions or early-stage disease. The lack of specificity is considered a fundamental hurdle for radiologic AI models, limited in their diagnostic capability due to subjectivity of the training data and accuracy of the readers' interpretation. Quantitative imaging, on the other hand, provides specific information about tissue characteristics on a pixel-by-pixel basis. These imaging techniques can measure precise amounts of elements such as iron, water, calcium, or fat in each region of interest. Imagion said that combining quantitative MRI sequences with its MagSense imaging agent could overcome one of the biggest obstacles to AI in medical imaging. MagSense particles attach to cancer cells, creating a unique, measurable signal that can be distinguished from healthy tissue automatically. This could lead to earlier and more accurate cancer diagnoses, reduce differences in how individual radiologists interpret scans, and make advanced imaging available beyond specialised medical centres The company said including these quantitative sequences in its phase II trial for HER2 breast cancer will accelerate development of AI diagnostics by providing early data to train and refine AI models. Exciting time for Imagion Imagion chief business officer Ward Detwiler said the company was very excited to have the collaboration and support of Haacke's research team. 'Dr Haacke literally wrote the book on MRI, which anyone in the MRI space will recognise as required reading,' he said. 'Combining their knowledge and expertise in quantitative MRI with the specificity of our targeted MagSense imaging agents, we believe we can significantly improve the diagnostic utility of the images by introducing quantitative data to enable precise, AI-based detection.' This article was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Imagion teams up with Wayne State University for AI push into cancer detection
News.com.au
10-07-2025
- Business
- News.com.au
Lunch Wrap: ASX shrugs off US trade concerns; Nvidia and Bitcoin surge
ASX up 0.62% at lunch time, with miners leading gainers US markets shrug off White House's latest tough tariff stance Imagion moves closer to phase II trial for HER2-positive breast cancer in US The ASX 200 is up 0.81% to 8607.40 points at 1pm AEST, supported by strength in heavyweight miners and banks. Property stocks are leading the day's gains. On Wall Street, the tech-heavy Nasdaq closed nearly 1% higher at a new record, driven by AI giant Nvidia hitting US$4 trillion in intraday trade. The S&P 500 rose 0.6%, while the Dow Jones added 0.5%. The US market rally has, for now, brushed aside concerns about the White House's aggressive global trade stance, suggesting traders are hopeful that negotiations will prevent a full-blown trade war ahead of Trump's new August 1 deadline. And Bitcoin has also rallied, surging above US$110,100, after reaching a new high of just north of US$112k during US trade. Oh, and just in case you're interested in the Aussie dollar… it's trading at around US65.42c. Seven of the 11 ASX sectors were in the green at lunchtime in the eastern states… ASX SMALL CAP WINNERS Here are the best performing ASX small cap stocks for July 10 : Code Description Last % Volume MktCap IBX Imagion Biosystems 0.023 84% 127,261,663 $2,516,768 YRL Yandal Resources 0.155 70% 505,541 $28,140,383 OB1 Orbminco Limited 0.0015 50% 500,050 $3,402,568 PAB Patrys Limited 0.0015 50% 253,372 $2,365,810 CC9 Chariot Corporation 0.077 40% 508,948 $6,564,457 DY6 Dy6 Metals 0.3 30% 4,978,961 $17,126,375 MEM Memphasys Ltd 0.005 25% 400,040 $7,934,392 MTB Mount Burgess Mining 0.005 25% 120,680 $1,702,553 RAN Range International 0.0025 25% 1,000,000 $1,878,581 VFX Visionflex Group Ltd 0.0025 25% 198,851 $6,735,721 SUM Summit Minerals 0.055 22% 446,772 $3,985,924 CCA Change Financial Ltd 0.085 21% 2,806,965 $48,079,711 CDE Codeifai Limited 0.029 21% 1,876,726 $11,255,728 MSG Mcs Services Limited 0.006 20% 624,534 $990,498 SIS Simble Solutions 0.006 20% 749,250 $5,411,652 PRS Prospech Limited 0.019 19% 314,659 $6,061,214 ACM Aus Critical Mineral 0.065 18% 259,931 $2,531,913 ANR Anatara Ls Ltd 0.007 17% 33,857 $1,280,302 RDS Redstone Resources 0.0035 17% 1,979,680 $3,102,802 KAL Kalgoorliegoldmining 0.043 16% 1,100,290 $14,123,237 SRL Sunrise 1.02 16% 225,263 $101,466,147 KM1 Kali Metals 0.099 15% 88,036 $7,124,881 PUA Peak Minerals Ltd 0.062 15% 20,118,547 $156,995,350 LKO Lakes Blue Energy 1.03 14% 247,057 $60,087,935 JAT Jatcorp Limited 0.4 14% 78,432 $29,143,331 Imagion Biosystems (ASX:IBX) has moved up in morning trade after announcing it had received formal written feedback from the US Food and Drug Administration (FDA), taking the company a step closer to initiating its phase II clinical trial for HER2-positive breast cancer in the US. The FDA has provided constructive input on Imagion's MagSense HER2 imaging agent study, helping to shape the clinical trial design and expected outcomes. Imagion's clinical team is set to meet with the regulator in person in the coming week to finalise the formal review process for trial ahead of an investigational new drug (IND) application. Results from Yandal Resources' (ASX:YRL) aircore drilling across the Caladan target area at the Arrakis prospect have confirmed mineralisation continuity along strike and reinforced the potential of the large-scale target area. Key intercepts include 11m at 2.1g/t gold from 90m in hole 25IWBAC023, including 7 metres at 3.1g/t from 92 metres. Additional results from hole 25IWBAC032 returned 12m at 1.1g/t from 45m, including 2m at 3.2g/t from 45m and 1m at 2.5g/t from 53m. YRL said results support the exploration upside across the broader Arrakis system. ASX SMALL CAP LAGGARDS Here are the worst performing ASX small cap stocks for July 10 : Code Name Price % Change Volume Market Cap IS3 I Synergy Group Ltd 0.001 -50% 2,056,454 $3,207,679 WEL Winchester Energy 0.001 -50% 100,000 $2,726,038 AYM Australia United Mining 0.002 -33% 980,000 $5,527,732 PIL Peppermint Innovation 0.002 -33% 2,658,474 $6,903,269 RCM Rapid Critical 0.002 -33% 2,000,000 $4,247,334 AM7 Arcadia Minerals 0.018 -28% 4,000 $2,934,586 AOA Ausmon Resorces 0.0015 -25% 143,271 $2,622,427 BMO Bastion Minerals 0.0015 -25% 9,750,000 $2,635,636 CTO Citigold Corp Ltd 0.003 -25% 10,000 $12,000,000 1AD Adalta Limited 0.002 -20% 114,000 $2,678,291 IMR Imricor Med Sys 1.26 -19% 1,623,591 $498,294,077 PNT Panthermetalsltd 0.009 -18% 5,487,277 $3,309,950 ADR Adherium Ltd 0.005 -17% 140,090 $8,321,749 AUK Aumake Limited 0.0025 -17% 48,279 $9,070,076 ECT Env Clean Tech 0.0025 -17% 12,361 $12,046,306 ERA Energy Resources 0.0025 -17% 1,192,012 $1,216,188,722 IPB IPB Petroleum Ltd 0.005 -17% 548,000 $4,238,418 PFE Pantera Lithium 0.02 -17% 18,517,346 $11,370,809 PRM Prominence Energy 0.0025 -17% 195,000 $1,459,411 SHE Stonehorse Energy Lt 0.005 -17% 400,000 $4,106,610 ADD Adavale Resource Ltd 0.026 -16% 845,459 $3,545,269 AZL Arizona Lithium Ltd 0.006 -14% 2,128,455 $36,892,201 GTR Gti Energy Ltd 0.003 -14% 1,838,000 $10,496,324 NAE New Age Exploration 0.003 -14% 37,315,454 $9,470,690 SVY Stavely Minerals Ltd 0.012 -14% 1,347,091 $7,616,589 LAST ORDERS GTI Energy (ASX:GTR) now has $2.5m of a $4.5m placement in the bank as it awaits the expected shareholder approval of the $1.487m committed by Nasdaq-listed US uranium and nuclear player and GTI neighbour Snow Lake Energy. The company is also expecting to be approved for drilling into its ISR uranium project in Wyoming next month after submitting permits to the relevant authorities and will soon look towards shareholder approval for a share consolidation and a name change as it establishes its slice of the US yellowcake industry. DY6 Metals (ASX:DY6) will mobilise the drill teams for an extended reconnaissance programme over its recently expanded Central rutile project in Cameroon after the continued reveal of natural rutile and mineral sands. Neighbouring Peak Minerals (ASX:PUA) has recently shown off some high-grade returns, and DY6 technical consultant Cliff Fitzhenry said that while a project-wide soil sampling campaign was still very much the plan, it decided to rapidly mobilise the crews to check out the northern portion of its licenses - with a strong suspicion the same mineralisation extends onto its own territory. Aura Energy (ASX: AEE) has shored up the board effective immediately with the appointment of former Mauritanian Finance Minister and Minister of Economic Affairs and Promotion of Productive Sectors Ousmane Mamoudou Kane as an independent Non-Executive Director. Aura managing director and CEO Andrew Grove said the company was honoured to welcome Kane to the board, and that his depth of experience in economic development and investment strategy in Mauritania and further abroad would add significant strength as it takes its Tiris uranium project to production. IN CASE YOU MISSED IT EZZ Life Science Holdings (ASX: EZZ) has inked a research services deal with the University of Sydney for study on effects on bone growth. Green Technology Metals (ASX:GT1) is confident that it's well placed for a lithium market rebound as it advances cost-effective workstreams over its prospective Canadian lithium projects and a strategic review of its portfolio. ClearVue Technologies (ASX:CPV) is set to form a strategic partnership with LandGlass Technology Co subsidiary LandVac after signing an MoU with the company known for its high-performance, vacuum-insulated glass. Norwest Minerals (ASX:NWM) has expanded its gold inventory at the Bulgera gold project by 33%, adding 70,800 ounces as it sits on the verge of drilling towards another upgrade northwards of Meekatharra. Chariot Corporation (ASX:CC9) is snapping up a quartet of new Nigerian lithium projects, a move which can open up an uncommon access to the lucrative Africa-China lithium supply chain. Decidr AI Industries (ASX:DAI) has entered a contract and partnership with AIM-operating Scentia Australia and achieved a key milestone in its growth trajectory. Green Critical Minerals (ASX:GCM) has first revenue in its gaze from the Very High Density graphite tech which boasts global electronics applications from semiconductors to thermal solutions. Imagion Biosystems (ASX:IBX) shares have leapt to attention after the company received positive feedback from the US FDA for its HER2 breast cancer phase II clinical trial. White Cliff Minerals (ASX:WCN) is preparing to unlock the large-scale red metal potential of its Rae project in Canada's Nunavut territory with the beginning of diamond drilling. At Stockhead, we tell it like it is. While GTI Energy, DY6 Metals, Peak Minerals and Aura Energy are Stockhead advertisers, they did not sponsor this article.
